Conference Correspondent
At the National Comprehensive Cancer Network 20th Annual Conference, Mario E. Lacouture, MD, presented some clinical pearls that can guide the management of dermatologic toxicities.
Felicia Zook, PharmD, BCOP, discussed her medical practice’s successful development and implementation of a pharmacist-driven drug-monitoring protocol at the 11th annual Hematology/Oncology Pharmacy Association conference.
Michael Koraleski, PharmD, outlined the proposed standards of the newest US Pharmacopeial Convention (USP) Chapter 800 at the 11th annual Hematology/Oncology Pharmacy Association conference.
- Abiraterone and Metabolic Syndrome
- Obesity and Survival in Metastatic Renal-Cell Carcinoma
- Radium-223 and Pain
- New Biomarker for Survival
- Quality of Life in Long-Term Survivors of Bladder Cancer
A successful pharmacist-driven drug-monitoring protocol can be achieved in a medical practice when necessary elements are considered.
Michael Koraleski, PharmD, outlined the proposed standards of the newest US Pharmacopeial Convention (USP) Chapter 800 at the 11th annual Hematology/Oncology Pharmacy Association conference.
Handling and disposing of oral cancer therapies can be hazardous, and certain protocols should be followed to reduce risks, according to Lisa Holle, PharmD, who spoke at the 11th annual Hematology/Oncology Pharmacy Association (HOPA) conference.
At the American Society for Blood and Marrow Transplantation’s (ASBMT) 2015 BMT Tandem Meetings, 4 studies were named the “Best Pharmacy Abstracts,” and are summarized here for our readers.
The American Society for Blood and Marrow Transplantation (ASBMT) Pharmacy Special Interest Group (SIG) is rapidly growing in both membership and opportunities, according to Jamie F. Shapiro, PharmD, BCOP, Clinical Pharmacy Coordinator, Stem Cell Transplant, and Chair of the ASBMT Pharmacy SIG.
To what extent should the pharmacist be included in hospice and palliative care, and how can their skills and knowledge best be utilized?